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ABSTRACT 
 
 
A prominent theory for the pathology of Huntington’s Disease (HD) involves 
excitotoxic injury to the striatum. Continuous exposure of ionotropic NMDA receptors to 
glutamate from the cortex may occur and be excitotoxic in HD and leave striatal neurons 
vulnerable to damage. Activation of presynaptic mGluR2/3 receptors by an agonist 
dampens glutamate release from corticostriatal terminals. Treatments that target 
excitoxicity thus may improve symptoms in HD patients, and it is therefore logical to 
pursue therapies aimed in this direction.  LY379268 is an inviting mGluR2/3 receptor 
agonist that has been shown to be neuroprotective in hypoxic and ischemic injuries to 
cultured neurons. Daily subcutaneous injection of 20mg/kg LY379268 had a number of 
beneficial effects in R6/2 mice, including an 11% improvement in lifespan and numerous 
locomotor parameters in open field. The motor parameters improved included overall 
activity, speed, acceleration, and endurance, all of which were normalized until 12 weeks 
of age, and improved over vehicle-treated R6/2 mice at all ages. Histological analysis 
revealed a 20% loss of cortical and striatal neurons in R6/2 mice, which was rescued with 
the administration of LY379268. There was no effect of the drug on neuronal intranuclear 
inclusions (NIIs) or benefit for ENK+ striatal neuron neurochemistry, but SP+ striatal 
projection neurons were normalized in their neurochemistry. The data indicate that 
LY379268 is particularly useful in improving the health and functioning of the direct 
striatal pathway (i.e. SP+ neurons), which demonstrably improved the voluntary motor 
behavior in the R6/2 mice. 
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CHAPTER 1.  INTRODUCTION 
 
 
Huntington’s disease (HD) is an inherited neurodegenerative disorder resulting in 
motor, cognitive and psychiatric abnormalities.  The progressive nature of the disease 
eventually leads to a disorder of extrapyramidal movement that includes the uncontrolled 
dance like motion of chorea, and later rigidity and dystonia (Cepeda et al 2007; Vonsattel 
& DiFiglia 1998).  Chorea is an early characteristic symptom which can be defined as 
excessive spontaneous movement with abrupt irregular timing.  It is repetitive in nature 
and all parts of the body can be affected by this symptom.  Dystonia is another motor 
abnormality seen later in HD with sustained muscular contraction.  Depression is a 
frequent psychiatric symptom and often precedes the appearance of motor abnormalities.  
Over years, the motor symptoms predominantly worsen, such that walking, speaking and 
eating become more difficult. Average age of onset is usually mid-thirties to mid-forties 
and the disease lasts 15-20 years.  This autosomal dominant disease stems from expanded 
polyglutamine (CAG) repeats in exon 1of the human HD gene (MacDonald 1993).  CAG 
is the codon for glutamine, and this trinucleotide repeat is responsible for the 
polyglutamine moiety within the huntingtin protein. Normal range of the expanded 
glutamine (polyQ) tract is between 25-35 repeats, with HD symptoms appearing with 
polyQ tracts greater than 35 repeats (Group 1993).  There is an inverse correlation 
between the length of the CAG repeats and the age of onset of HD (Group 1993; Telenius 
et al 1993), and repeat lengths greater than 70 produce an HD phenotype characterized by 
juvenile onset, and rigidity, dystonia and tremor as presenting symptoms.  
 
Although the HD protein huntingtin (htt) was discovered over a decade ago, its 
function is still not fully understood.  The protein coded by the HD gene is ubiquitously 
expressed throughout the body and has widespread subcellular localization, thus 
contributing to the difficulty in determining its function. However, many proteins interact 
with htt, which can offer clues to elucidate the function of htt and the pathogenesis of 
HD.  These protein-protein interactions are based on the shape of the three-dimensional 
structure of huntingtin and the poly-Q expansion in the N-terminal region (Poirier et al 
2005).  Based on their known functions, htt-associated proteins can be grouped as 
proteins that are involved in gene transcription and proteins that are involved with 
intracellular signaling, trafficking, endocytosis or metabolism (Li & Li 2004a).  This 
involvement means that htt is associated with a variety of cellular structures including the 
nucleus, endoplasmic reticulum, Golgi complex, synaptic vesicles and mitochondria 
(DiFiglia et al 1995; Gutekunst et al 1998; Velier et al 1998).  Wild type htt undergoes 
four types of post-translational modifications: sumoylation and ubiquination of lysines at 
the N-terminal, phosphorylation of serines; and palmitoylation at an unknown amino acid 
(Huang et al 2004; Humbert et al 2002; Kalchman et al 1996; Steffan et al 2004).  
Huntingtin also contains three protease cleavage sites leading to fragments of both 
normal and mutant huntingtin (mhtt) (Wellington et al 2002).  It was found that N-
terminal mhtt forms aggregates in the nucleus and the cytoplasm, whereas full-length 
mhtt is diffuse in the cytoplasm of brain cells (DiFiglia et al 1997; Sharp et al 1995).   
The structure of the N-terminal fragments arises from the inherent protein misfolding 
conferred by the polyQ expansions and the resulting pathology is still being explored. 
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Although it has been difficult to define the precise role of huntingtin, its role in 
embryonic development has been demonstrated.  After the discovery of the HD gene it 
was shown that a complete knockout of the gene is embryonically lethal (Duyao et al 
1995).  Mutant huntingtin is not entirely dysfunctional, since it can rescue the embryonic 
lethal phenotype seen in the huntingtin-null knockout mice (Dragatsis et al 1998).  
 
 
Pathology of Huntington’s Disease 
 
Although wild-type (WT) and mutated huntingtin protein is ubiquitously 
expressed in many neuronal subtypes, the medium spiny neurons (MSN) of the striatum 
and to a lesser extent, the pyramidal neurons of the cortex are more vulnerable to 
degeneration, thus contributing to the clinical symptoms of the disease. Although there is 
widespread brain atrophy from cell loss, the cortex and striatum are most heavily 
affected. The striatal atrophy leads to enlargement of the lateral ventricles. Since MSNs 
encompass 90% of neurons in the striatum, there is a hallmark degeneration of this region 
of the basal ganglia with accompanying pathological changes in the thalamus and 
subthalamic nucleus (Hedreen et al 1991; Vonsattel & DiFiglia 1998). Gliosis and 
atrophy are also seen in the substantia nigra pars reticulata. The striatum receives a large 
glutamatergic and trophic input from the cortex, and this connection can serve as a 
possible contributor to the resulting pathology.  In addition to the changes in the striatum 
there is atrophy of the cortex and thalamus in late stages of the disease (Vonsattel & 
DiFiglia 1998).  
 
Within the striatum, HD differentially affects subpopulations of neurons, with 
projection neurons preferentially being lost rather than interneurons (Albin et al 1990; 
Difiglia 1990). Studies have shown early in the disease process that projection neurons 
that contain both enkephalin (ENK) and gamma-aminobutyric acid (GABA) are lost 
more rapidly than those that contain substance P (SP) and GABA (Deng et al 2004). The 
significance of this observation is enkephalin/GABA-containing neurons project to the 
external globus pallidus (GPe) and constitute the striatal part of the indirect pathway, 
whose normal activation suppresses unwanted movement.  In early HD, thus, the function 
of the indirect pathway is predominantly disrupted, and basal ganglia circuitry models 
predict an overall increase in unwanted movement, manifested as chorea. This finding 
provides an anatomical substrate for the increased adventitious movement that is the 
hallmark of HD (Albin et al 1992; Deng et al 2004; Reiner et al 1988).  The substance 
P/GABA-containing striatal neurons project to the internal globus pallidus and the 
substantia nigra, and thus constitute the striatal part of the direct pathway, whose 
activation promotes planned, appropriate movement.  In later stages of adult HD, both 
populations of striatal projection neurons are affected (Reiner et al 1988), and both 
akinesia predominates.   
 
 Huntington’s disease is also characterized by the presence of neuronal 
intranuclear inclusions (NIIs) in striatal and cortical neurons (DiFiglia et al 1997).  These 
aggregates consist of the N-terminal fragments of mhtt and appear early in the disease 
process, often before other phenotypes (Vonsattel & DiFiglia 1998). It is the cleavage of 
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the mhtt N-terminals that promote this aggregation and it is brought about by activation 
of proapoptotic caspases (Wellington et al 2002). NIIs are also present in several 
transgenic HD mouse lines with a similar appearance before behavioral phenotypes. It 
was found that N-terminal htt fragments expressed in transgenic animals or cultured cells 
are more toxic than full-length htt (Davies et al 1997; Hodgson et al 1999; Schilling et al 
1999). It is still unresolved if the aggregates are the cause of clinical symptoms or are the 
result of a protective mechanism that sequesters mutant protein. 
 
 
Pathogenesis of Huntington’s Disease 
 
Since the gene has been discovered, there has been intense effort to find out why 
the predominant pathology of HD by mhtt is limited to the brain and particularly affects 
striatal neurons. One theory is that death in neurons occurs through apoptosis, that is, 
activation of a programmed cell death pathway triggered by mitochondrial dysfunction. 
There is evidence that indicates that WT htt triggers molecular events that lead to 
increased cell survival.  Such pro-survival mechanisms include the inhibition of pro-
caspase 9 and, and a pro-apoptotic protein, huntingtin-interacting protein 1, by WT htt 
(Gervais et al 2002; Rigamonti et al 2000; Zhang et al 2006).  Mitochondria play a role 
in the process of caspase activation and apoptosis. 3-nitroproprionic acid  (3-NP) is an 
irreversible inhibitor of mitochondrial complex II, and causes apoptotic neuronal death 
through the release of cytochrome-c with consequent activation of caspases (Almeida et 
al 2006).  Injection of 3-NP or malonate (a reversible mitochondrial complex II inhibitor) 
into the striatum leads to neuronal loss resembling that in HD (Beal et al 1993; Shear et 
al 1998). In human post mortem analysis, DNA fragmentation characteristic of apoptosis 
has been described in HD brain (Thomas et al 1995). Although these findings are 
promising for understanding HD pathogenesis, it is not yet clear if apoptosis is the 
principle event responsible for striatal cell death in HD.  
 
Theories of HD pathogenesis also implicate excitotoxicity or energetic 
dysfunction.  Glutamate is responsible for excitatory synaptic transmission in the central 
nervous system by acting upon three classes of ionotropic receptors:  N-methyl-D-
aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA), and 
kainate receptors.  The selective loss of striatal projection neurons could come about due 
to overactivity of the vast glutamatergic input from the cerebral cortex, while striatal 
interneurons, which are less affected in HD, have fewer excitatory inputs. MSNs showed 
an increased NMDA current density and swelling compared to interneurons in striatal 
slices from HD mutant mice (Cepeda et al 2001).  This suggests that continuous exposure 
of ionotropic NMDA receptors to glutamate can be excitotoxic in HD and leave striatal 
neurons vulnerable to damage.  The NMDA receptor is important in synaptic plasticity as 
well as cell death due to its voltage dependent magnesium block and high calcium 
permeability (Bliss & Collingridge 1993).  Excessive stimulation causes an influx of 
calcium ions, leading to activation of enzymes that degrade proteins and cause cell death 
(Berliocchi et al 2005).  Striatal NMDA receptor function is enhanced in the R6/2 and 
other transgenic HD models (Cepeda et al 2001; Laforet et al 2001; Levine et al 1999).  
Presynaptic group II metabotropic glutamate (mGluR2 and mGluR3) receptors located at 
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the corticostriatal terminals are capable of regulating the release of glutamate (Calabresi 
et al 1996; Cepeda et al 2001).  The mGluR2/mGluR3 receptors belong to heterogeneous 
family of glutamate receptors that are linked to GTP-binding proteins, and this particular 
class is negatively coupled to cyclic AMP production (Nakanishi 1992).  It is known that 
mGluR2 receptors are located presynaptically and can negatively modulate glutamate 
release (Battaglia et al 1997).  Activation of these receptors by an agonist reduces 
excitatory-post-synaptic-potentials (EPSPs) in striatal neurons (Calabresi et al 1996), thus 
dampening the effect of glutamate release from corticostriatal terminals.  Any alteration 
of these receptors could lead to a pathological increase of glutamate release, and it was 
discovered that there is a decreased expression of mGluR2 and mGluR3 receptors in the 
transgenic HD mouse R6/2 (Cha et al 1998).  
 
Excitotoxicity can also come about due to decreased clearance of extracellular 
glutamate from the synaptic cleft.  This uptake of glutamate is carried out via the EAAT2 
transporter by glial cells.  There is a decrease of this transporter and the enzyme 
glutamine synthetase in HD mice (Lievens et al 2001).  Glutamine synthetase is primarily 
found in astrocytes in the brain and aids in diminishing excitoxicity of neurons by uptake 
of excessive glutamate (Suarez et al 2002).  Mutant huntingtin also is present in glial 
cells, and it was shown that there is an increase neuronal vulnerability among neurons  
cultured with astrocytes expressing mhtt as opposed to neurons cultured with astrocytes 
expressing wild-type htt (Shin et al 2005). 
 
Normal huntingtin has been linked to brain derived neurotrophic factor (BDNF) 
via different mechanisms involving BDNF transcription and vesicular transport.  This 
protein is important for the survival of striatal neurons (Widmer & Hefti 1994).  BDNF is 
co-localized with huntingtin in cortical neurons that project to the striatum and most 
striatal BDNF is produced in the cerebral cortex (Altar et al 1997; Baquet et al 2004; 
Fusco et al 2003).  Wild-type huntingtin promotes the vesicular transport of BDNF along 
microtubules via huntingtin-associated-protein 1(HAP1) (Gauthier et al 2004), and 
BDNF transport to striatum is thus impaired in HD.  Evidence for pathogenesis stemming 
from diminished BDNF production in the cortex and transport to striatum comes from 
multiple HD mice.  Reduced cortical mRNA levels for BDNF and reduced cortical and 
striatal protein levels are found in YAC mice (Zuccato et al 2001), R6/2 mice (Zuccato et 
al 2005), and mutant huntingtin knock-in mice (Gines et al 2003).  These data indicate 
that decreased BDNF transcription occurs in HD.  It was shown that mhtt reduces the 
transcription of several exons of BDNF in the cortex due to both loss of wild type 
huntingtin and a toxicity of the mutant protein (Zuccato et al 2001; Zuccato et al 2005).  
Baquet et al showed behavioral and striatal changes with a cortical BDNF knock-out 
mouse model that paralleled the neurological dysfunction seen in R6/2 mice (Baquet et al 
2004).  
 
 
Therapies in Huntington’s Disease 
 
It is challenging to perform therapeutic trials in HD patients for a variety of 
reasons.  Since there is a low prevalence of the disease, recruitment of a sufficient 
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number of patients is difficult. The disease has a slow progression so potential drugs that 
might have a benefit require a long follow up. It is important that all original therapies are 
tested in cell cultures and animal models before being moving to clinical trials. Although 
it is not known what causes death of striatal neurons and sickness of cortical neurons in 
HD as discussed in previous sections, there are novel ideas being tested with various 
kinds of therapies.  The ability to screen for new agents has advanced rapidly with 
understanding of HD pathogenesis.  Among methodologies, yeast and cell culture models 
are inexpensive and lend themselves to rapid testing.  Studies typically begin by 
screening compounds on cultured neurons for efficacy.  High throughput assays screen 
for molecules that target specific pathways (such as huntingtin aggregation in vitro) or 
that block cell toxicity (Apostol et al 2003; Murphy et al 2000).  Potential therapeutic 
agents are being identified in studies of excitotoxic and mitochondrial toxin models of 
HD.  A strategy is to move these compounds to a more realistic model than cell cultures 
and a number of agents have been shown to be effective in transgenic mouse models of 
HD.  In light of the strong evidence of excitotoxic damage in HD as discussed earlier, an 
in vivo model offers a better choice to test ideas about excitotoxicity.   
 
 A valid in vivo model should show a measureable progression of pathology 
replicating mid- to late-life onset of motor impairment.  The R6/2 HD mouse is a good in 
vivo model because it replicates several phenotypes and neuropathologies seen in 
humans, including a progressive motor and cognitive impairment (Bolivar et al 2003; 
Carter et al 1999; Murphy et al 2000), ubiquitinated nuclear and cytoplasmic inclusions 
of mhtt (Davies et al 1997; Li et al 1999), and decreased brain and striatum size 
(Mangiarini et al 1996).  In a microarray study of postmortem human HD cases, it was 
found that R6/2 mice reproduce the transcriptomic changes of human HD (Kuhn et al 
2007).  This animal model has been shown to have a decrease in cortical mGluR2/3, 
which is capable of contributing to excitotoxicity (Cha et al 1998). As discussed earlier, 
an increased NMDA receptor-mediated current could lead to excitotoxic effects and 
activation of a presynaptic cortical autoreceptor could limit this effect.  R6/2 mice were 
also shown to have a decrease in measured ENK-immunoreactive fiber intensity in GP 
when compared to wild type mice at 12 weeks of age (Sun et al 2002).  This may be 
indicative of an early stage of striatal neuron degeneration in adult onset HD (Reiner et al 
1988; Sapp et al 1995).  Sun et al found elevated SP-immunoreactive fiber intensity in 
SN of R6/2 at 12 weeks of age, which counters that found in adult-onset HD.  This could 
reflect a dysfunction in release of SP by striatonigral neurons (Sun et al 2002).  Volume 
changes of brain regions are also reflected in the transgenic models.  There is a 41% 
striatal volume reduction and total brain reduction of 44% of R6/2 mice at 90 days (Stack 
et al 2005).  This is accompanied by a 26% striatal neuron loss.  Preliminary studies with 
the R6/2 transgenic mouse showed that this model develops several progressive motor 
pathologies (Mangiarini et al 1996).  These included progressive hypoactivity, resting 
tremors, abrupt and shuddering movements, epileptic seizures, foot clasping and 
dyskinesia of hindlimbs upon tail suspension (Carter et al 1999).  
 
Precise and definable measured patterns of movement and locomotion are critical 
endpoints in assays with HD mice.  Open field assays test many motor and behavioral 
endpoints, and many of these traits are affected in HD.  Since the pathology exists in the 
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basal ganglia, open-field testing is beneficial for evaluating the complexity of exploratory 
behavior.  The Golani and Drai automated open field task allows rapid and automatic 
measurement of many aspects of locomotion (Drai & Golani 2001).  These measured 
parameters include bursts of locomotion called progression segments and pauses termed 
lingering episodes.  The velocities of the progression segments and the number of stops 
are calculated for an open field session.  The use of SEE (Software for the Exploration of 
Exploration) allows the parameters to be isolated and quantified.  Measured endpoints 
reflect processes of navigation, motivation, locomotion, spatial memory and learning 
(Drai & Golani 2001).  Rotarod is another assay that measures coordination and balance. 
R6/2 mice have difficulty maintaining balance on the device at 5-6 weeks of age (Carter 
et al 1999; Luesse et al 2001).  One caveat of the test is that there is a cerebellar 
component to completing the task (Crawley 1999).  Other endpoints to measure that 
reflect overall health are weight loss and lifespan.  When compared to wild type (WT) 
littermates, the R6/2 transgenic mice show a decline in body weight after 10 weeks of 
age.  Lifespan for this model is 10-13 weeks (Carter et al 1999; Mangiarini et al 1996).
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CHAPTER 2.  RESEARCH OBJECTIVES AND SPECIFIC AIMS 
 
 
Excessive glutamate release from cortical terminals in striatum can result in a 
pattern of injury that is similar to the one seen in Huntington’s disease. Previous work 
was shown that the R6/2 Huntington’s disease (HD) mouse model has an enhanced 
striatal NMDA receptor-mediated current (Cepeda et al 2001).  The increased activation 
of striatal neurons can result in an excitotoxic loss of medium spiny neurons in the 
striatum.  One method to curtail this increase is the use of an mGluR2/3 receptor agonist.  
Activation of this receptor, which is localized to cortical terminals in striatum, decreases 
the release of glutamate and thus dampens excitotoxic effects (Calabresi et al 1996).  
 
An inviting drug for HD therapy is an mGluR2/3 agonist.  There is evidence that 
mGluR2/3 agonists have significant neuroprotective potential.  Administration of 
LY379268 (a mGluR2 agonist) was shown to limit ischemic and hypoxic injury (Bond et 
al 1999; Kingston et al 1999).  Excitotoxic injury involves the same caspases that are 
involved in HD and thus lends credence to LY379268 being a good choice of 
experimental therapeutics to limit neuronal death in HD.  In a previous study, LY379268 
showed a benefit on lifespan but not rotarod performance in R6/2 HD transgenic mice 
(Schiefer et al 2004).  While these results are promising, the study was limited in several 
ways.  The drug was dosed at 1.2mg/kg dissolved in water, and then given orally to the 
subjects via an applicator tube in the upper esophagus.  A question can be raised if 
maximal benefit can be achieved from LY379268 from such a low dose.  The 
neuroprotective effects of LY379268 were seen in other studies with dosings much 
higher than 1.2mg/kg as used by Schiefer et al (Bond et al 1999; Cai et al 1999; Kingston 
et al 1999).  The study used NIIs as a histological endpoint, and found no differences in 
distribution and size of NIIs among R6/2 mice given LY379268 or a placebo.  The 
authors used NIIs as the only morphological measure of pathological changes in HD 
mice, while there are other known phenotypical changes that can be considered, such as 
distinct volume changes and neuronal abundance.  A complete study should include 
measurements of these other morphological changes.  Behavioral testing in the Schiefer 
study included an open field assay which showed a decline in hyperactive spontaneous 
locomotion with LY379268 administration as compared to control mice. It is possible 
that more improvement could be observed with a higher dose of the drug and more 
sophisticated behavioral testing.  There are many approaches that measure locomotion 
and motor skills more robustly than used by Schiefer et al (2005).  A study is needed 
showing the efficacy of a higher dose of LY379268 on behavioral endpoints and 
numerous morphological pathologies.  Some of the treatments that target excitoxicity and 
oxidative stress which have shown to be beneficial in transgenic mouse models may 
improve some of the symptoms in HD patients and it is therefore logical to pursue 
therapies aimed in this direction.  A more detailed exploration of the ability of LY379268 
to reverse the behavioral, motor and histological abnormalities in the R6/2 is carried out 
with this series of experiments.  All of the fixed-tissue histological and morphometric 
data collection was completed by me, while the behavioral work and in situ hybridization 
(ISH) was carried out by other personnel in the lab, but the behavioral and ISH results are 
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presented in this thesis because they are a critical adjunct to the histological data in 
giving a complete picture of potential therapeutic outcomes with LY379268. 
 
The aims of the project were: 
 
 Aim 1:  To test the hypothesis that LY379268 can normalize known changes in 
histological endpoints.   
 
 Aim 2:  To test the hypothesis that LY3979268 can normalize the lifespan, body 
weight, behavioral and motor abnormalities seen in the R6/2 mouse model.   
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CHAPTER 3.  EXPERIMENTAL PROCEDURES 
 
 
Subjects 
 
R6/2 mice, which bear a transgene for the 5’ end of the human HD gene carrying 
about 150 CAG repeats and including the promoter region, were obtained from Jackson 
Laboratories (Bar Harbor, ME).  A colony was maintained by breeding R6/2 mice with 
CBA X C57BL/6 F1 (B6CBAF1) mice, thereby obtaining offspring that were 
hemizygous for the transgene and wild-type littermates.  Mice were genotyped and CAG 
repeat length determined using a PCR-based amplification method (Sun et al 2002).  
R6/2 and WT mice were randomly assigned to either control treatment with vehicle or 
treatment with LY379268.  Daily subcutaneous injections of LY (20mg/kg) began after 
genotyping at PND21.  Thirty-four mice were used in the four treatment groups for the 
fixed-tissue histological analysis.  Seventy-seven mice were used in the four treatment 
groups for behavioral analysis.   
 
 
Tissue Fixation 
 
Under deep anesthesia (avertin; 0.2 cc/g body weight), transgenic R6/2 mice and 
wild-type mice were perfused transcardially with 60 ml of 6% dextran in 0.1 M sodium 
phosphate buffer at pH 7.4 (PB), followed by 200 ml of 4% paraformaldehyde, 0.1 M 
lysine-0.1 M sodium periodate in 0.1 M PB (PLP).  The brains were removed and stored 
for at least 24 hours in a 20% sucrose/10% glycerol solution at 4°C.  The fixed brains 
were sectioned frozen on a sliding microtome in the transverse plane at 35 µm.  Each 
brain was collected as 12 separate series in 0.1 M PB 0.02% sodium azide and stored 
until processed for immunohistochemistry.  A series of sections from the brain of each 
mouse was stained for cresyl violet to study normal brain histology. 
 
 
Immunohistochemistry 
 
Immunohistochemical labeling was carried out to characterize abnormalities in 
cortex or striatum.  Immunohistochemical single-labeling for ubiquitin, to visualize NIIs 
in R6/2 mice, was carried out using a peroxidase-antiperoxidase (PAP) procedure 
described previously (Anderson & Reiner 1990).  Immunolabeling was also used for 
NeuN for neuron labeling, substance P (SP) for SP+ striatal projection systems, and 
enkephalin (ENK) for ENK+ striatal projection systems.  To carry out 
immunohistochemical labeling, sections were incubated for 24 hours at room temperature 
in primary antiserum diluted 1:2000–1:5,000 with 0.3% Triton X-100/0.02% sodium 
azide/0.1 M PB (PBX).  Sections were then rinsed and incubated in donkey anti-mouse 
IgG or anti-rabbit IgG (depending on the primary antiserum) diluted 1:50 in PBX, 
followed by incubation in the appropriate mouse or rabbit PAP complex diluted 1:200 in 
PBX, with each incubation at room temperature for 1 hour.  The sections were rinsed 
between secondary and PAP incubations in three 5-minute washes of PB.  Subsequent to 
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the PAP incubation, the sections were rinsed with three to six 10-minute washes in 0.1 M 
PB, and a peroxidase reaction using diaminobenzidine tetrahydrochloride (DAB) was 
carried out.  Sections were incubated in 5 ml of 0.05 M imidazole/0.05 M cacodylate 
buffer (pH 7.2) containing 5 mg DAB for 10 minutes and then incubated for an additional 
10 minutes after adding 20 µl of 3% hydrogen peroxide, with continuous agitation 
throughout.  Sections were then washed in distilled water, placed in 0.1 M PB, mounted 
onto gelatin-coated slides, dried, dehydrated, and cover slipped with Permount. 
 
 
Microscopic Analysis 
 
 
NII Frequency and Size 
 
Sections immunolabeled for ubiquitin from R6/2 mice and wild-type mice were 
analyzed for NII size and frequency.  This analysis was carried out blinded to the 
treatment groups.  For each mouse, images of primary motor cortex and striatum were 
captured from each of three sections, one at the level of rostral striatum, one at the level 
of the midstriatum, and one just behind the anterior commissure using a 40X objective on 
an Olympus BH-2 microscope, a Spot camera, and a Mac computer.  These images were 
used to determine NII frequency (number of NIIs per field), size, and percent of the field 
occupied by NIIs for the cortex and striatum. Three adjacent images of primary motor 
cortex were captured and analyzed for each level, with analysis performed separately on 
layers II/III, V, and VI.  For striatum, images of central, dorsomedial, ventromedial, 
dorsolateral, and ventrolateral striatum were analyzed for each level.  Frequency and 
percent of the field occupied by NIIs was determined by thresholding NIIs using Image-J 
software (from U.S. National Institutes of Health, available at http://rsb.info.hih.gov/nih-
image).  NII size (i.e., diameter) was also measured for cortex and striatum using Image-
J. Artifacts in the images were removed prior to thresholding, and the size of the 
thresholded NIIs was assessed using the Particle Measurement function of NIH Image.  
 
 
Volume Measurements 
 
Blinded examination of sections through the rostral telencephalon suggested 
lateral ventricular expansion and striatal shrinkage in the R6/2 brains. To evaluate this 
quantitatively, image analysis was blindly carried out to determine the volume of the 
telencephalon, cerebral cortex, lateral ventricle, striatum, and septum for the rostral 
telencephalon (i.e., from the end of the olfactory bulb to the level just behind the anterior 
commissure).  For each mouse an image of each section in a one-in-six series from the 
rostral telencephalic pole to the level of just behind the anterior commissure, at which 
levels the lateral ventricles are narrow in normal mice, was captured at high resolution 
(4800 dpi) using a Epson scanner.  NIH Image was used to measure the areas occupied 
by the entire telencephalon, the cerebral cortex, the lateral ventricles, the striatum, and 
the septa on each side of the brain.  The cerebral cortex was measured from the midline to 
the rhinal fissure from pial surface to external capsule.  The striatum was defined by the 
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contours of the external capsule and globus pallidus, while the septum was defined as the 
region between the corpus callosum and a horizontal line connecting the ventral tips of 
the ventral horns of the lateral ventricles.  Section thickness and spacing were used to 
determine the volume of each structure from the areal measurements in the cross-section.  
Because brain size is correlated with brain size, comparisons of absolute brain size of the 
above individual brain areas between R6/2 mice and WT mice is confounded by the 
smaller size of R6/2 mice.  To correct for this, we present the volume data divided by 
body weight raised to the 0.66 power (the allometric scaling exponent for the relation of 
body size to brain size) (Lande, 1979).   
 
 
Image Analysis of Immunolabeling in Striatal Target Areas 
 
To assess injury to the neurons of origin of the striatal projection systems, 
quantitative computer-assisted image analysis was carried out on immunolabeled striatal 
terminals in each of the main striatal projection targets, blindly to treatment group.  For 
these studies, the areal extent and immunolabeling intensity of the ENK+ fiber plexus in 
the GPe and the SP+ fiber plexuses in the GPi and substantia nigra were quantified. For 
GPe, its ENK+ plexus in the 2-4 sections spanning its rostrocaudal extent were captured 
bilaterally.  For GPi, images of the entire GPi from 1-2 sections spanning its rostrocaudal 
extent were bilaterally captured for analysis.  For substantia nigra, the entire nigra in 2-4 
sections spanning its rostrocaudal extent were captured and analyzed bilaterally.  The 
immunolabeled fibers in these striatal target areas were highlighted and the area occupied 
by them and their labeling intensity determined using the thresholding and optical density 
measuring capabilities of Image-J.  To correct for slight variations in image intensity 
stemming from variations in lighting during image capture and/or from variations in the 
staining protocol, the background intensity of the captured images was standardized to a 
value of 100 on the 0-255 gray scale employed by the Image program using the image 
editing capabilities of this program.  The region of each image used to set the background 
intensity was an area of unlabeled white matter within the field of view.  For GPe and 
GPi the external capsule was used for optical density standardization, while for images of 
the substantia nigra the cerebral peduncle was used.  Fiber abundance for a given 
structure in a given case was expressed as the mean percent of the structure occupied by 
labeled fibers for all measurements for that case.  Fiber abundance for each target area for 
each HD case was then expressed as a percent of control. 
 
 
Stereology 
 
Stereological neuron counts were carried out blindly to the treatment groups of 
the mice.  A one-in-six series immunolabeled for NeuN from just behind the olfactory 
bulb to the level of the anterior commissure were used for striatal and cortex neuron 
analysis.  Landmarks were as those noted above for the volume measurements.  Unbiased 
stereological counts of striatal and cortical neurons were obtained by using Neurolucida 
Stereo Investigator software (Micro-Brightfield, Colchester, VT).  The dissector counting 
method was used where counting frames are taken from a random series of evenly spaced 
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sections.  These counting frames are chosen by the software within predefined areas used 
for demarcating the volumes of the striatum and cortex.  
 
 
Behavioral Analysis 
 
 
Rotarod 
 
Rotarod was performed at the same time of the day to be consistent with the 
diurnal activity phase.  During the training period, each mouse was placed on an 
accelerating rotarod starting at 0 rpm and accelerating gradually up to 30 rpm at 240 
seconds.  This maximum velocity was maintained for an additional 120 seconds.  Mice 
received four training trials during the first session, by which time a steady baseline level 
of performance was achieved.  Rotarod sessions were run twice a week, with x trials per 
session after the first four-trial training session.  The trial was considered over when a 
mouse fell off the rotarod or when it stayed on the rod for a maximum of 360 seconds.  
The latency to fall off was recorded and used in subsequent analysis.  
 
 
Open Field 
 
A circular open field arena with a diameter of 180 cm and 60 cm high walls was 
used to evaluate locomotor activity of the mice.  Each mouse was placed in the arena for 
a 30-minute trial once a week.  A mouse was placed near the wall and its behavior in the 
arena was recorded throughout the session by a stationary video camera whose lens 
covered the whole cylinder field.  The locomotor path traversed by the mouse was 
recorded by an automated tracking system using Ethovision, and analyzed by SEE 
software.  The SEE software extracted a number of locomotor parameters of interest, as 
presented here, including length and duration of locomotor bursts called progression 
segments, time spent locomoting (activity), duration and time spent lingering, speed and 
acceleration during progression segments, and spatial distribution of progression 
segments. 
 
 
Statistical Analysis 
 
The body weight, rotarod and open field data were analyzed statistically using 
SAS software and a mixed model ANOVA, considering genotype, drug, gender and their 
interactions in the analysis.  Data for the immunohistochemical studies were analyzed 
statistically by ANOVA followed by Fisher PLSD individual group comparisons, 
reciprocal transforming data as need to normalize distributions.  
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CHAPTER 4. RESULTS 
 
 
Histological Studies of Fixed Tissue 
 
The effects of LY379268 were blindly analyzed on telencephalic, cortical, striatal 
and lateral ventricular volumes.  Other parameters included neuron abundance in cortex 
and striatum, neurochemical integrity of striatal projections systems, and NII size and 
frequency.  The completed analysis included 8-10 LY-treated R6/2 mice (average CAG = 
119.1), 9-10 vehicle-treated R6/2 mice (average CAG = 118.3), 9-10 LY-treated WT 
mice, and 8-11 vehicle-treated WT mice. 
 
 
Volumetric Analysis 
 
Volumes were measured blindly from the end of the olfactory bulb to the level 
behind the anterior commissure.  The R6/2 mice had a smaller body mass.  To correct for 
the impact of this on brain size, and determine if the R6/2 genotype and/or the drug 
treatment affected brain part size, brain volumes were expressed using an allometric 
correction. Brain and body weights are related by the following allometric equation 
“brain = κ(body)α” where α = 0.67 (Lande, 1979).  Thus, dividing brain size by body 
weight raised to the 0.67 power corrects for the impact of body size variation on brain 
size. 
 
As shown in Table 1, telencephalic volumes differed among the groups, but were 
similar between the R6/2 vehicle-treated and WT vehicle-treated mice.  This data set 
shows that WT-LY treated group telencephalic volume was greater (69.1mm2) than in 
any other group, but the telencephalic size reflected a larger body size.  The allometric 
correction shows that this increase is not significant since corrected telencephalic volume 
is 104.9% of that in WT-V.  The average measured volumes of cortex in R6/2 mice were 
slightly smaller than in WT mice, but the difference was not significant.  Treatment with 
the LY compound did not produce a significant effect on cortex volume in either the WT 
or R6/2 mice compared to the vehicle-treated mice.  Volume of the striatum in R6/2-LY 
mice was, however, less than in vehicle-treated WT mice.  There was a significant and 
large increase in ventricular volume in both R6/2 mice groups in contrast to WT mice. 
Treatment with LY379268 did not cause a significant decrease in ventricular volume in 
the R6/2 mice compared to the vehicle-treated R6/2 mice.  These various results are 
shown in Table 1. 
 
 
Neuron Counts 
 
The neuron abundance for cortex and striatum was significantly less in the R6/2 
vehicle as compared to the WT vehicle treated mice (85% and 83.7%, respectively).  
Stereological neuron counts also showed significantly fewer neurons in vehicle-treated 
R6/2 mice than LY-treated R6/2 mice in cortex and striatum.  Cortical and striatal neuron 
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Table 1. Volumetric Analysis 
 
Mouse Treatment 
Groups 
# of 
Mice 
Telen 
Volume in 
mm2 
Body 
Weight in 
Grams 
Telen 
Volume / 
Body 
Weight 
Telen 
Volume / 
(Weight).67 
Cortex 
Volume / 
(Weight).67 
Striatum 
Volume / 
(Weight).67 
Ventricle 
Volume / 
(Weight).67 
Septum 
Volume / 
(Weight).67 
WT - Vehicle 8 62.0 21.8 2.92 100% 100% 100% 100% 100% 
WT – LY379268 9 69.1 23.8 2.94 104.9% 107.8% 100.7% 114.5% 109.6% 
R6/2 – Vehicle 9 62.2 22.3 2.82 99.4% 96.9% 99.6% 250.9%*^ 106.5% 
R6/2 – LY379268 8 60.6^ 20.7 2.95 99.1% 92.8% 87.9% 236.7%*^ 99.7% 
 
Note: *significantly different from WT-Vehicle; ^significantly different from WT-LY379268 
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abundance, however, did not differ between the WT mice and the LY-treated R6/2 mice.  
Thus, there was about a 20% decrease in neuron abundance in striatum and cortex of 
R6/2-vehicle mice, which was rescued in the R6/2 mice by daily injections of 20mg/kg of 
LY379268 (Table 2).   
 
 
Striatal Projection Systems 
 
Immunohistochemical analysis of striatal projection neurons were measured by 
thresholding of the terminals projecting to the external pallidal segment (GPe) for 
enkephalin, internal pallidal segment (GPi) or substantia nigra (SN) for substance P.  This 
labeling technique allows measurement of peptide abundance within these striatal targets.  
A benefit of the LY drug on R6/2 mice was seen in the SP projection neurons. 
 
 
Striatonigral 
 
As shown in Table 3, the percentage of nigra covered by SP fibers in R6/2-vehicle 
mice is significantly larger than in WT-V mice (39%) or WT-LY mice (42.4%).  Daily 
injections of LY379628 reduced the percentage of nigra covered by SP fibers so it was 
not significantly different from the WT groups, but was less than in R6/2-V mice (21.9% 
lower).  The intensity of SP labeled fibers in nigra is significantly elevated in the LY-WT 
group and the two R6/2 groups compared to the Vehicle-WT group.  The intensity 
elevation in the WT-LY group indicates that the LY drug did affect SP+ striatonigral 
neurons in WT mice.  Immunolabeling intensity is a reflection of the amount of peptide 
present, and in this case it is likely it reflects a failure of release, in both the WT-LY mice 
as well as the R6/2 mice groups, as explained in the Discussion.  The pattern of SP 
immunolabeling in these mouse groups is illustrated in Figure 1.  Note that in the R6/2-
vehicle mice SP+ fibers cover the entire nigra, but in both the WT-Vehicle and R6/2-LY 
mice a lateral part of the nigra is notably poor in SP.  
 
 
Striato-GPi 
 
As shown in Table 4, SP+ fiber coverage was significantly greater in striato-GPi 
of R6/2-vehicle mice (106% of WT-V) compared to WT-LY mice (95.9% of WT-V), but 
SP+ fiber coverage was at WT-vehicle levels in R6/2 mice treated with LY379268 
(101.6% of WT-V). This is consistent with the trend observed in striatal projection 
terminals in the nigra, but less dramatic.  These data as well suggest that LY379268 
normalizes SP+ fiber abundance in GPi in R6/2 mice.  The intensity of SP labeling was 
significantly increased in striatal terminals in GPi of LY-treated WT mice (117.2%) as 
compared to WT-vehicle treated mice (100%).  Thus, mGluR2/3 agonism significantly 
increased SP+ labeling in striato-GPi terminals in WT mice, which we interpret as 
diminished SP release due to diminished corticostriatal activation of striato-GPi neurons. 
The intensity of SP immunolabeling in striato-GPi terminals was also significantly  
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Table 2. Neuron Counts 
 
Group Number of 
Mice 
Cortical Neuron 
Count 
Cortical 
Neuron as % 
WT 
Striatal Neuron 
Count 
Striatal Neuron 
as % WT 
WT – 
Combined 
21 448,700 100% 231,157 100% 
R6/2 – 
Vehicle 
10 381,411.3* 85% 193,588.2* 83.7% 
R6/2 – 
LY379268 
10 461,906.5# 103.4% 241,399.8# 104.4% 
 
Note: *significantly different from WT; #significantly different from R6/2-Vehicle 
 
 
 
17 
 
Table 3. Effect of LY379268 on Striatal Projection Neurons in Nigra of R6/2 Mice 
 
Mouse 
Groups 
# of 
Mice 
Mean 
Repeat 
Length 
% of Nigra Covered by 
SP+ Fibers from Direct 
Pathway Neurons 
Intensity of SP+ Fibers in 
Nigra Arising from Direct 
Pathway Neurons  
WT –
Vehicle 
8 N/A 100% 100% 
WT – 
LY379268 
8 N/A 96.6% 114.8%* 
R6/2 – 
Vehicle 
9 118.3 139.0%*^ 115.5%* 
R6/2 – 
LY379268 
8 119.1 117.1%# 111.8%* 
 
Note: *significantly different from WT-Vehicle; ^significantly different from WT-
LY379268; #significantly different from R62-Vehicle 
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Figure 1. SP in Nigra 
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Table 4. Effect of LY379268 on Striatal Projection Neurons in GPi of R6/2 Mice 
 
Mouse 
Groups 
# of 
Mice 
Mean  
Repeat 
Length 
% of GPi Covered by 
SP+ Fibers from Direct 
Pathway Neurons 
Intensity of SP+ Fibers in 
GPi Arising from Direct 
Pathway Neurons  
WT –
Vehicle 
8 N/A 100% 100% 
WT – 
LY379268 
9 N/A 95.9% 117.2%* 
R6/2 – 
Vehicle 
9 118.3 106.0%^ 122.4%* 
R6/2 – 
LY379268 
8 119.1 101.6% 120.4%* 
 
Note: *significantly different from WT-Vehicle; ^significantly different from WT-
LY379268 
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increased in both R6/2 mice groups, which is likely to be an effect of the genotype of 
striato-GPi neuron activity.  
 
 
Striato-GPe 
 
Coverage of GPe with immunolabeled ENK+ fibers in R6/2 – vehicle treated 
mice was significantly less than in WT-V mice (92.5% of WT-V).  While seemingly 
similarly reduced in R6/2-LY mice (93.4%), this was not significantly different than WT-
V.  The fiber coverage in the two WT groups was not significantly different.  There were 
no significant differences among the four groups in ENK+ fiber intensity in GPe. Overall, 
these results indicate no major effect of genotype on ENK+ fibers in GPe, and no major 
effect of LY379268 on the ENK+ fibers in GPe in either WT or 6/2 mice.  These results 
are shown in Table 5. 
 
 
Mutant Protein Aggregation 
 
Measurements were carried out for ubiquitin immunolabeling of NIIs in 6 LY-
treated R6/2 and 9 vehicle-treated mice.  Measurements of NIIs were only carried out on 
the R6/2 mice, as NIIs do not form in WT mice.  There were no significant differences in 
frequency (area of field covered by NIIs) or NII size in cerebral cortex or striatum 
between vehicle-treated and LY379268-treated R6/2 mice.  For example, the percent of 
the field covered by NIIs was 1.27% in R6/2-V mice and 0.82% in R6/2-LY mice.  
Similarly, the percent of the field covered by NIIs in the striatum was 0.63% for R6/2 
mice receiving LY379268 and 0.51% in vehicle treated R6/2 mice.  The average NII size 
in the cortex of R6/2-LY was 2.09μm, and R6/2-Vehicle in 2.06μm, which is not 
significant.  Similarly, NII size in the striatum of R6/2-LY mice was 1.54μm, and in 
striatum of R6/2-Vehicle mice was 1.61μm.  While Schiefer et al (2004) reported that NII 
size in R6/2 mouse cortex was increased 20% using the same agonist, the current study 
demonstrated no evidence that LY379268 affects nuclear aggregate formation. 
 
 
Histological Studies of Unfixed Tissue 
 
The in situ hybridization (ISH) data was completed by Hong Bing Wang and is 
presented here for completeness. Tissue was analyzed that had been fresh-frozen ISH 
processed using digoxigenin detection with riboprobes for ENK and SP ISH from 10 
WT-vehicle mice, 11 WT-LY mice, 10 R6/2-vehicle mice, and 11 R6/2-LY mice.  All 
mice were 10 weeks old, and the labeling was analyzed using computer-assisted imaging 
and the Image-J analysis program.  Data were analyzed statistically by ANOVA followed 
by Fisher PLSD individual group comparisons, reciprocal transforming data as need to 
normalize distributions.   
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Table 5. Effect of LY379268 on Strial Projection Neurons in GPe of R6/2 Mice 
 
Mouse 
Groups 
# of 
Mice 
Mean  
Repeat 
Length 
% of GPe Covered by 
ENK+ Fibers from 
Indirect Pathway 
Neurons 
Intensity of ENK+ Fibers 
in GPe Arising from 
Indirect Pathway Neurons  
WT –
Vehicle 
8 N/A 100% 100% 
WT – 
LY379268 
8 N/A 97.1% 109.0% 
R6/2 – 
Vehicle 
9 118.3 92.5%* 106.5% 
R6/2 – 
LY379268 
8 119.1 93.4% 108.6% 
 
Note: *significantly different from WT-Vehicle 
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ENK In Situ Hybridization Analysis 
 
No significant differences were seen between WT-LY compared to WT-vehicle 
mice in total striatal ENK signal.  Thus, LY379268 did not affect ENK+ striatal neurons 
in a way that affected ENK message in WT mice.  By contrast, in R6/2-V mice overall 
striatal signal was greatly and significantly reduced (32.4% of WT-V).  The overall 
striatal signal was also similar in the R6/2-LY mice, and was also significantly less than 
in WT-V (32.5% of WT-V).  The ENK signal per perikaryon also did not differ between 
wildtype groups, but was reduced by about 50% in both R6/2 groups.  Thus, as in the 
case of our ENK immunolabeling of the indirect pathway striatal projection to GPe, there 
was no benefit of LY379268 treatment for the ENK+ striatal neuronal population.  These 
results are seen in Table 6. 
 
 
SP In Situ Hybridization Analysis 
 
 As in the case of ENK message, no significant differences were seen between 
WT-LY compared to WT-vehicle mice in total striatal SP signal.  Thus, LY379268 did 
not affect SP+ striatal neurons in a way that affected SP message in WT mice (Table 7).  
Total SP+ signal in the striatum of R6/2-V was 84.4% of WT-V, while in R6/2 mice 
receiving LY379268 total striatal SP+ signal was elevated to 14.3% above WT-V.  
Similarly, SP signal per perikaryon was reduced to 81.5% of WT-V in the R6/2-V mice, a 
significant reduction, but was not significantly different form either WT group in the 
R6/2-LY mice.  Thus, by both immunolabeling and ISH, the data indicate LY379268 to 
benefit SP+ striatal neurons in R6/2 mice. 
 
 
Behavioral Analysis 
 
 
Survival 
 
Figure 2 shows cumulative survival for the thirty-two 20mg/kg LY-treated (LY) 
and 30 control-treated R6/2 mice.  The benefit of daily 20mg/kg LY379268 is evident. 
Lifespan was studied in 32 R6/2 mice treated with 20mg/kg of LY379268 daily, 17 R6/2 
mice with vehicle, and 13 R6/2 mice with 10mg/kg LY379268.   There was no significant 
difference in survival benefit between the R6/2 mice treated with 10mg/kg of LY and the 
vehicle treated group, thus these two groups were combined and compared with the R6/2 
mice treated with 20mg/kg of LY379268.  This dose was selected as the maximum 
tolerated dose (MTD) in tests on R6/2 mice carried out prior to the benefit assessments, 
using an MTD protocol recommended by the funding agency for this research, the Cure 
HD Initiative Foundation.  The average CAG repeat length was 124.0 for the LY-treated 
R6/2 mice, and 123.6 for the control-treated R6/2 mice. There was no significant 
difference between CAG repeat lengths between males and females.  The mean survival 
was significantly longer in the 20mg/kg LY-treated than the control-treated R6/2 mice 
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Table 6. LY379268 on ENK in Striatal Projection Neurons as a % of WT-Vehicle 
 
Mouse 
Groups 
# of 
Mice 
Mean Repeat 
Length 
Intensity of ENK+ ISH 
Signal per Perikaryon  
Total ENK+ Signal 
in Striatum 
WT – Vehicle 10 N/A 100% 100% 
WT – 
LY379268 
9 N/A 103.8% 107.9% 
R6/2 – 
Vehicle 
9 123.8 49.6%*^ 32.4%*^ 
R6/2 – 
LY379268 
11 124.7 50.3%*^ 32.5%*^ 
 
Note: *significantly different from WT-Vehicle; ^significantly different from WT-
LY379268 
 
 
 
 
Table 7. LY379268 on SP in Striatal Projection Neurons as a % of WT-Vehicle 
 
Mouse Groups # of 
Mice 
Mean Repeat 
Length  
Intensity of SP+ ISH Signal 
per Perikaryon 
Total SP+ Signal in 
Striatum 
WT - Vehicle 10 N/A 100% 100% 
WT – 
LY379268 
10 N/A 96.7% 90.3% 
R6/2 – 
Vehicle 
8 123.9 81.5%*^ 84.4% 
R6/2 – 
LY379268 
10 124.7 90.2% 114.3%# 
 
Note: *significantly different from WT-Vehicle; ^significantly different from WT-
LY379268; #significantly different from R6/2-Vehicle 
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Figure 2. Survival 
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(88.5 days in drug-treated vs. 79.7 days in control-treated), by Mantel-Cox logrank test (p 
= 0.0276). There was a 9-day benefit for males and female mice treated with 20mg/kg of 
LY.  Measured lifespan was 4 days less on average with males in both the control group 
and those receiving 20mg/kg of LY.   
 
 
Body Weight 
 
Figure 3 shows that mean body weight was persistently slightly lower in the 19 
LY-treated WT mice (red) than in the 19 vehicle-treated WT mice (blue).  This becomes 
apparent after 8 weeks.  The 32 R6/2 mice treated with LY379268 (green) had a lower 
body weight than the 30 control R6/2 mice beginning at 13 weeks of life.  Statistical 
analysis, however, did not show a significant effect of drug on body weight throughout 
the testing period, nor for the R6/2 mice at 14-16 weeks (p = .08).  Thus, any effect of 
drug on body weight is slight and variable.  ANOVA analysis did not reveal a significant 
effect of the drug-genotype interaction, indicating that any effects on body weight of 
20mg/kg LY were similar irrespective of gender.  There were however, significant effects 
of gender (males heavier than females in WT, females heavier than males in R6/2) and 
genotype (WT heavier than R6/2) on body weight. 
 
 
Rotarod Performance 
 
Figure 4 shows that LY379268 did not improve rotarod performance in 32 R6/2 
mouse treated with a daily 20mg/kg dose.   There was no discernable benefit of rotarod 
performance between LY and Vehicle treated R6/2 mice as seen with the blue and red 
lines in the figure. The R6/2 mice have an inferior performance at all time points when 
compared to the WT mice.  The drug did not hinder rotarod performance in WT mice.   
 
 
Open Field Measurements 
 
 
Total Distance Traveled in Centimeters during 30 Minutes 
 
As seen in Figure 5, vehicle-treated R6/2 mice locomote much less than WT mice 
during the 30-min session (i.e. are less active and cover less total distance), and the LY 
drug yielded better performance in R6/2 mice on this endpoint than observed in the 
vehicle-treated R6/2 mice at all ages.  Of particular note, the LY drug normalized total 
locomotor activity until about 12 weeks of age.  The benefit was comparable in males and 
females.  The drug did not have an obvious deleterious effect on the WT mice in their 
total distance traveled.  These observations were confirmed by ANOVA, which detected 
significant effects of genotype, drug and the drug-genotype interaction on distance 
traveled. 
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Figure 3. Effect of LY379268 on Body Weight 
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Figure 4. Rotarod Performance 
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Figure 5. Total Distance Traveled in Centimeters during 30 Minute Session 
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Median Progression Segment Length 
 
Figure 6 shows an underpinning of the decreased distance traveled in vehicle-
treated R6/2 mice, in that it shows that vehicle-treated R6/2 mice traversed shorter 
distances during their bursts of locomotion (called progression segments in the Drai and 
Golani lexicon) than did normal mice.  Treatment of LY397268 in R6/2 mice showed an 
improvement in this parameter and progression segment length increased over those  
measured in WT mice between weeks 8 and 12 of life.  These observations were 
confirmed by ANOVA, which detected significant effects of genotype, drug and the 
drug-genotype interaction on progression segment length. 
 
 
Time Proportion Spent Lingering 
 
Figure 7 shows that vehicle-treated R6/2 mice spent a greater proportion of the 
time between progression segments in pauses called lingering episodes than did WT 
mice.  These pauses contributed to the overall decrease in activity in the vehicle-treated 
R6/2 mice.  Note that the total proportion of time spent lingering is greater in vehicle-
treated R6/2 than WT mice, and increases as the mice age.  ANOVA confirmed a benefit 
of LY379268, with less lingering occurring, since significant effects of genotype, drug 
and genotype-drug interaction occur for the 9-17 week period (when the defect in 
vehicle-treated R6/2 mice becomes prominent). 
 
 
Progression Segment Maximum Speed 
 
Figure 8 shows that maximum locomotor speed during progression segments was 
much less in vehicle-treated R6/2 mice than in WT mice, and progressively worsened as 
the R6/2 mice approached the end of their lifespan.  The LY drug strikingly improved 
R6/2 mice on this motor parameter.  ANOVA confirmed a benefit of LY379268 in R6/2 
mice on maximum locomotor speed, since significant effects of genotype, drug and 
genotype-drug interaction were observed. 
 
 
Median Curvature of Progression Segments 
 
Figure 9 shows that vehicle-treated R6/2 mice had increasing difficulty walking in 
a straight line (i.e. the curvature of their progression segments was increased), and also 
shows that the LY compound strikingly normalized R6/2 mice on this parameter for 
much of their lifespan.  Beyond 15 weeks, path curvature in vehicle-treated R6/2 was 
diminished, as the shorter progression segments in the few surviving vehicle-treated mice 
may have made it easier for the mice to walk a straight line.  ANOVA confirmed that for 
the period over which vehicle-treated R6/2 mice showed a progressive impairment, the 
drug was beneficial in the R6/2 LY-treated mice, since significant effects of drug, and 
drug-genotype interaction were seen for the 9-15 week period.   
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Figure 6. Median Progression Length 
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Figure 7. Time Proportion Spent Lingering 
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Figure 8. Maximum Progression Speed 
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Figure 9. Median Curvature of Progression 
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CHAPTER 5. DISCUSSION 
 
 
Our results show several benefits of daily injections of an MTD of LY379268 in 
R6/2 mice.  These beneficial effects of this mGluR2/3 agonist include normalized motor 
parameters at 4-12 weeks in the open field task, including normalized speed, acceleration, 
endurance and overall activity.  Morphological improvement was seen as well in terms of 
rescue of cortical and striatal neurons, and normalization of the SP+ striatal projection 
neurons was apparent at 10 weeks.  The results for SP neurons are particularly interesting 
because SP neurons are part of the direct pathway which is responsible for voluntary 
movement (Albin et al 1992; Reiner et al 1988).  Impairments to this pathway result in 
hypoactivity (Alexander & Crutcher 1990; DeLong 1990; Reiner et al 1988), and it is 
possible that a defect in this pathway contributed to the decline of open field activity in 
R6/2 mice that was observed.  It is particularly interesting to note, thus, that the akinesia 
of the R6/2 mice (e.g. reduced open field activity) was accompanied by the normalization 
of the SP pathway.  These findings will be discussed in more detail below, as well as the 
means by which the LY compound could have produced its improvement. 
 
  
Neuropathology and Behavior Correlations 
 
The phenotype and neuropathology of R6/2 mice replicate several features of the 
disease observed in humans, including altered levels of neurotransmitters and 
neuropeptides in the basal ganglia (Cha 2000).  As in HD, the striatal projection neurons 
of R6/2 mice are not uniformly affected over the course of the disease (Cha et al 1998; 
Luthi-Carter et al 2000; Menalled et al 2000).  Immunohistochemistry has shown in 
human HD that ENK and SP levels differ in their target areas based on the stage of the 
disease (Reiner et al 1988).  ENK fibers projecting to the GPe are lost sooner than SP 
fibers projecting to GPi (Deng et al 2004; Reiner et al 1988).  Analysis of the GPe in 
R6/2 mice at 12 weeks of age also showed a decrease in ENK labeled fibers in GPe, but 
no significant change was reported in the measured SP labeled fibers (Sun et al 2002).  
Our study of R6/2 mice at 10 weeks of age showed a slightly elevated SP-
immunoreactive fiber intensity for striatal projection fibers to GPi and a substantial 
elevation for SN.  This increase for SP-immunolabeled fibers projecting to SN has been 
depicted in other studies, but has not been commented upon (Menalled et al 2000; Sun et 
al 2002).  Our in situ hybridization data for 10-week R6/2 mice showed a significantly 
decreased overall message for ENK (30% of WT) and slight decrease in SP (85% of WT) 
message in striatum.  This matches previous in situ hybridization studies on 12-week 
R6/2 mice that showed enkephalin mRNA is reduced in striatal neurons to a greater 
extent than substance P mRNA (Menalled et al 2000; Sun et al 2002).  Similarly, a 
microarray study of R6/2 mice at 12 weeks of age showed a decreased expression of 
enkephalin mRNA from striatum, but no major changes were seen in Substance P mRNA 
(Luthi-Carter et al 2000).  Such results show that the increase in SP in the GPi and SN do 
not stem from an increase in SP production.  An interpretation is that the increase in SP in 
striato-GPi and striato-SN reflects a failure of peptide release, since less mRNA is being 
made, yet more peptide is present in the terminals.  An argument could be made that the 
35 
 
SP retention in R6/2 striatal projection neuron terminals thus reflects neuronal 
dysfunction.  Previous immunohistochemical studies have shown that ablation of 
corticostriatal neurons results in increased SP levels of SN in rats (Bouras et al 1991; 
Somers & Beckstead 1990).  These authors attribute this effect to a loss of cortical 
activation of striatal neurons, with a subsequent diminution of SP release (Bouras et al 
1991).  Alterations in the firing activity of neurons have been observed in the striatum of 
awake- behaving R6/2 mice that may account for the failure of peptide release in striatal 
target areas.  In particular, Rebec and coworkers have noted that MSNs of R6/2 mice are 
slightly more active than in WT mice, but they fail to show the type of burst activity that 
ensues from cortical activation (Miller et al 2008; Rebec et al 2002).  Burst activity, 
which represents spike clusters of varying rates and duration, provide information coding 
by assemblies of neurons (Sakurai 1999; Salinas & Sejnowski 2001).  Burst firing 
ensures reliable transmission between neurons and induces synaptic plasticity in the 
striatum (Charpier & Deniau 1997; Lisman 1997).  This dysregulation of firing could 
alter downstream neurotransmitter release of either ENK or SP projection neurons.  In the 
present study, daily injections of LY379268 rendered SP levels in SN down to 130% of 
WT as opposed to the level of 160% seen with vehicle-treated R6/2. Likewise, SP levels 
in LY-treated R6/2 mice were down in GPi to 122% compared to the vehicle-treated R6/2 
mice measured at 132%.  Thus, the LY379268 compound relatively normalized SP levels 
in GPi and SN. 
 
Our results show that ENK message is greatly reduced but an apparent retention 
of the peptide results in normal ENK levels in striato-GPe terminals, thus disguising the 
fact that less ENK is being made.  The retention is more obvious with the SP projection 
neurons because the message is not as greatly diminished, so the peptide retention yields 
peptide levels above normal.  Although SP peptide levels are relatively normalized with 
LY379268 in GPi and SN, the same effect is not seen with ENK levels in GPe.  This is 
consistent with our in situ hybridization data showing the LY compound normalized SP 
message but did not alter ENK message in R6/2 mice.  This implies that the LY379268 
benefit is specific to SP neurons. The Direct-Indirect pathway model of basal ganglia 
function (DeLong 1990) proposes that voluntary movement would be normalized with 
restored function of SP neurons, which our behavioral data reflects.  It would be of 
interest to know if burst firing is restored in R6/2 mice with administration of LY379268.  
Research has also shown that a modulator of striatal activity is extracellular levels of 
ascorbate (Rebec et al 2005; Rice 2000).  Ascorbate interacts with the glutamate 
transporter in a heteroexchange mechanism, whereby glutamate is taken up and ascorbate 
is transported out of astrocytes (Cortright & Rebec 2006; Grunewald & Fillenz 1984).  It 
would be interesting to know if striatal levels of ascorbate increase with administration of 
the LY379268.  
 
Although R6/2 mice show gross brain and striatal atrophy (Mangiarini et al 
1996), neuronal loss has only been reported in one study. Stack et al, (2005) showed a 
25% decrease in total number of striatal neurons in 12-week old R6 /2 mice.  Our current 
results show a 20% loss of striatal neurons in 10-week old R6/2 mice, which was 
normalized with administration of LY379268.  Although it has been suggested that 
neuron loss does not occur in R6/2 mice (Li & Li 2004b; Reddy et al 1999), differences 
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in methodology might account for the difference in outcomes.  Stereology as used in the 
current study was also used by Stack et al (2005), and is a more sensitive approach for 
detecting neuron loss.  A distinction could not be made with stereology, however, as to 
which population of striatal projection neurons was more decreased, but it would be 
interesting to know if the benefit seen in neuron rescue by the LY compound affected 
primarily the SP pathway.  
 
The R6/2 mouse typically shows enlarged lateral ventricles with coinciding 
striatal atrophy at 13 weeks (Mangiarini et al 1996).  Volumetric data on striatum, lateral 
ventricle, and cortex was expressed scaled allometrically to body weight, because of the 
effect of genotype on animal size.  By this standard, telencephalic and cortical volume 
did not differ among the groups, but ventricular size was doubled in the R6/2 mice.  
LY379268 treatment did not affect ventricular volume in the R6/2 mice.  The ventricular 
volume increase is suggestive of cortical, septal and/or striatal atrophy, but the only 
significant effect for any of these seen in the R6/2 mice was for striatal volume, which 
was about 10% smaller in the R6/2-LY mice.  Overall, these data indicate minimal 
cortical or striatal shrinkage in the R6/2 mice at 10 weeks, and no evident benefit of 
LY379268 in the R6/2 mice.  
 
 
Pathogenic Mechanisms 
 
There are a variety of means by which LY379268 could have produced its 
improvement. The compound may have opposed excitotoxic striatal injury (D'Onofrio et 
al 2001; Kingston et al 1999).  There are several possible ways it could have done this. 
Since there are mGluR2/3 receptors on cortical terminals, the drug may have acted by 
reducing presynaptic release of glutamate (Battaglia et al 1997; Cozzi et al 1997).  This 
alone would have an effect that would oppose excitotoxicity. In principle, reducing 
presynaptic glutamate release should reduce excitotoxicity, and reduce striatal pathology 
in HD.  One prior study prevented corticostriatal glutamate release in R6/2 mice by 
ablating cortical neurons and eliminated loss of striatal neurons and striatal shrinkage 
(Stack et al 2007).  LY379268 may have also acted directly on striatal neurons, because 
mGluR3 is found on some subset of striatal neurons (Testa et al 1994), although it has 
not been established which subset.  A third possibility for a mechanism of action is that 
LY379268 could have increased trophic substance production from striatal astrocytes.  In 
a prior study, TGF-β production was enhanced in striatal glial cells with administration of 
LY379268 (D'Onofrio et al 2001).  Another possible mechanism of action is that cortical 
BDNF was upregulated with the LY compound, as shown to occur in mice (Di Liberto et 
al 2010), which would be beneficial for striatal neurons (Canals et al 2004; Zuccato & 
Cattaneo 2007).  Each of these possible mechanisms will be addressed in further detail 
below.  
 
The notion that excess cortical glutamate release mediates striatal injury 
presupposes that striatal injury is caused by excitotoxicity, and many lines of evidence 
suggest this is so.  Since NMDA receptor agonists injected into striatum produce a 
pattern of striatal injury that closely mimics HD pathology (Figueredo-Cardenas et al 
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1994; Shear et al 1998), it has widely been thought that excitotoxicity is involved in HD. 
Several lines of research suggest HD pathology stemming from excitotoxic injury to the 
striatum is specifically mediated through extrasynaptic NMDA receptors on the striatal 
projection neurons.  Notably, NMDA current is enhanced in HD transgenic mice (Andre 
et al 2006; Cepeda et al 2001; Fan & Raymond 2007; Li et al 2004), and the enhanced 
NMDA response stems from increased expression of the extrasynaptic receptors NMDA 
of striatal projection neurons (Fan et al 2007).  Activation of these receptors requires 
glutamate spill from the synaptic sites to the extrasynaptic sites (Milnerwood et al 2010).  
Such activation can enhance mhtt cleavage in toxic fragments, and thus make neurons 
more vulnerable to death via decreased CREB-PGC-1α activity (Cui et al 2006; 
Milnerwood et al 2010; Papadia et al 2008; Subramaniam et al 2009).  Cleaved mhtt is 
soluble and binds to CREB binding protein, thus interfering with gene transcription 
(Nucifora et al 2001).  In mhtt-transfected neurons, CREB function was restored by 
selectively blocking the extrasynaptic NMDA receptors with low dose memantine 
(Okamoto et al 2009).  This same study also showed improved rotarod performance in 
YAC128 mice with this low dose (Okamoto et al 2009).  There seems to be an excitatory 
balance needed for neuroprotection since high dose memantine blocked beneficial 
synaptic NMDA receptor activity, thus increasing soluble mhtt and worsening the 
phenotype in this study (Okamoto et al 2009).  By contrast, low-dose memantine allowed 
synaptic receptor activation that was beneficial for cell survival, with consequences such 
as reducing soluble mhtt, increasing mhtt aggregate size and stimulating the CREB 
pathway (Okamoto et al 2009).  There is also altered glutamate release from 
corticostriatal synapses in HD mice prior to motor pathology (Cepeda et al 2003), and 
electrophysiological studies have shown an increase of glutamate release from 
corticostriatal terminals at an early age (Cepeda et al 2007; Joshi et al 2009).  Glutamate 
is normally taken up via excitatory amino acid transporters, in particular GLT1, (Shigeri 
et al 2004), and there is decreased expression of this transporter in astrocytes of HD mice 
and HD humans (Behrens et al 2002; Hassel et al 2008; Lievens et al 2000; Shin et al 
2005).  If LY397268 acts pre-synaptically for its benefit, then excess glutamate release 
and spillover would be attenuated, and less would reach the extrasynaptic NMDA 
receptors.  If the mechanism of action of the LY compound is post-synaptic (as discussed 
in the next paragraph), then the effect would dampen the activity of the striatal neurons 
and produce its benefit in that way.  Neither of these mechanisms gives a clear reason 
why our results showed a greater benefit on SP neurons rather than ENK neurons.  It was 
previously shown that upper layer V cortical neurons project specifically to striatal SP 
neurons (Lei et al 2004), but it is not clear if mGluR2/3 receptors are more abundant on 
that particular cortical neuron type.  
 
It is possible that the benefit of LY379268 arises by a direct action on striatal 
projection neurons.  An overview of the distribution and mechanism of action of the 
mGluR2/3 receptors in the striatum offers insight into the basis of potential benefit seen 
in our results.  Within the striatum, mGluR2 receptors are only found in cholinergic 
neurons and not projection neurons (Testa et al 1994).  The mGluR3 receptors in the 
striatum are on astrocytes as well as on neurons (Testa et al 1994).  It is of interest to note 
that examination of images in the Allen Brain Atlas indicates approximately 50% of the 
striatal neurons contain mGluR3, and it is known that approximately 50% of the striatal 
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projection neurons are SP neurons (Gerfen et al 1990; Reiner et al 1988).  If the SP 
neurons are the same neurons that contain mGluR3, then the benefit of LY379268 could 
be achieved by direct striatal action.  Activation of mGluR3 is coupled to inhibition of the 
cyclic AMP pathway (Nakanishi 1992; Schoepp et al 1999).  This results in decreased 
membrane excitability stemming from reduced Ca2+ current via N, L-type Ca2+ 
channels and increased K+ current via IRKC channels (Davies et al 1995; King & Liu 
1996; McCool et al 1996).  If the benefit of LY379268 was achieved in this manner, it 
should be possible to see the same effects if the R6/2 mice are treated with a dopamine 
D1 receptor antagonist, since this would also yield reduced activation of the cAMP 
pathway (Monsma et al 1990).  Further studies are needed to firmly establish the location 
of mGluR3 receptors on striatal projection neurons.  
 
 As mentioned above, the benefit of the LY compound could have come about by 
an increased production of TGF-β in the striatum.  It has been shown that activation of 
mGluR3 receptors mediates striatal neuroprotection via glial-neuronal interaction (Bruno 
et al 1997).  This neuroprotection comes about from TGF-β released from astrocytes, and 
is effective in preventing NMDA toxicity in in vitro and in vivo models (Bruno et al 
1997; Bruno et al 1998).  Systemic administration of LY379268 in mGluR3 knock-out 
mice failed to give neuroprotection to striatal neurons against NMDA toxicity (Corti et al 
2007).  This same study showed that the neuroprotection was abolished in cultured 
neurons with astrocytes lacking mGlur3 receptors (Corti et al 2007).  These studies 
suggest that activation of mGluR3 receptors on the striatal astrocytes offer 
neuroprotection.  The neuroprotection from TGF-β could also arise through a different 
mechanism other than preventing excitotoxicity, including preventing neuronal apoptosis 
(Copani et al 1995; Ren et al 1997).  Activation of TGF-β receptors leads to 
phosphorylation of Smad2, a transcription factor, which activates gene expression 
(Massaous & Hata 1997) involved with inhibiting cyclin-dependent kinases involved 
with cell cycle check points (Datto et al 1995).  This mechanism is relevant because 
inducing an abortive mitotic cycle has been related to the occurrence of neuronal 
degeneration (Freeman et al 1994; Herrup & Busser 1995).  A study showed that cyclin 
D1 and E2F-1 are over-expressed in brains of HD patients (Pelegri et al 2008).  There is 
evidence showing these two proteins are involved with abortive cell cycle re-entry in 
neurons (Camins et al 2007; Krantic et al 2005), with subsequent neurodegeneration due 
to oxidative stress and apoptosis (Pelegri et al 2008; Woods et al 2007; Zhu et al 2007).  
 
 In addition to TGF-β, BDNF increase by LY379268 administration could play a 
role in neuroprotection. BDNF is known to promote development, differentiation, 
plasticity and survival of neurons in several regions of the brain including striatum 
(Lessmann et al 2003; Poo 2001; Zuccato & Cattaneo 2007).  It is known that mhtt in HD 
reduces the transcription of the BDNF gene in the cortex of HD mice and thus decreases 
protein production (Zuccato et al 2001).  These authors showed that cortical BDNF 
mRNA decreased with progression of behavioral symptoms in R6/2 mice (Zuccato et al 
2005).  A study of a cortex specific knock-out model of the BDNF gene showed a 
progression of the disease that mimicked the pathology of human HD in terms of striatal 
degeneration (Strand et al 2007).  Conversely, behavioral performance was improved and 
disease progression slowed in an HD mouse crossed with mice overexpressing BDNF 
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(Gharami et al 2008).  These lines of evidence suggest that a deficit in BDNF contributes 
to the pathogenesis of striatal injury in HD, thus making it a candidate as a therapeutic 
agent.  Another study showed daily intrastriatal administration of BDNF in R6/1 HD 
mice increases the number of striatal neurons expressing enkephalin and resulted in 
improvement in behavioral phenotypes (Canals et al 2004).  Conversely, in R6/1 on a 
hemizygous BDNF knock-out background, striatal ENK expression but not SP 
expression is reduced (Canals et al 2004).  This suggests that endogenous BDNF might 
delay the progression of HD in humans.  A recent study showed mice acutely treated with 
LY379268 showed an upregulation of BDNF in cortex and hippocampus (Di Liberto et al 
2010).  The various lines of studies reviewed above give credence to the idea that the 
benefit from the LY compound stems from a possible increase in cortical BDNF in the 
mice.  Despite this evidence that BDNF must be involved with striatal neuron health, 
Stack et al (2007) showed that decortication in R6/2 mice improves striatal 
neuropathological phenotypes and restores striatal neuron loss to WT levels.  This argues 
against the idea that striatal neuron loss in R6/2 mice stems from BDNF deprivation 
because decortication would only exacerbate the BDNF deficit.  The study of Canals 
(2004) showing BDNF benefit for ENK but not SP neurons provides further evidence 
that BDNF was unlikely to have been the basis for our striatal benefit observed with 
LY379268 since a large benefit for striatal neurons containing ENK was not seen by us.  
The benefit of LY379268 in the present study was seen for striatal neurons containing 
SP.  It is likely thus that the striatal benefit of LY379268 does not involve a BDNF 
mechanism, since our results show little benefit with ENK neurons.  It is possible that the 
cortical BDNF upregulation caused by LY379268 benefits cortex, and explained the 
rescue of cortical neurons observed here. 
 
 
mGluR2/3 Therapy  
 
 In the past several years, group II metabotropic glutamate receptors have become 
a target of potential therapeutics.  Activation of these mGlur2/3 receptors can suppress 
presynaptic glutamate release in a negative feedback manner to keep glutamate 
transmission within a normal physiological range (Kew et al 2001; Scanziani et al 1997; 
Schoepp 2001).  The location of mGluR2/3 receptors at the periphery of the terminals 
allows monitoring of excess glutamate spillover from the active zone (Conn & Pin 1997).  
Developing a ligand with in vivo activity is necessary for preventing the hyper-
excitability from interfering with normal neuronal function.  The first selective agonist 
developed was LY354740 (Monn et al 1997) followed by LY379268, the latter of which 
has enhanced affinity for mGluR2/3 receptors (Monn et al 1999; Schoepp 2001).  
Metabotropic GluR2/3 are negatively coupled to adenyl cyclase, and thus agonists inhibit 
the production of cAMP (Monn et al 1997).  As a more potent agonist, LY379268 
suppresses cAMP formation on a magnitude of two orders higher than LY354740 (Monn 
et al 1999).  This same study also showed that LY35470 had equal affinity for mGluR2 
and mGlur3, while LY379268 is more selective for mGluR3 (Monn et al 1999).  The 
early studies of mGlur2/3 agonists looked at efficacy with regards to a benefit for 
neuroprotection and ischemia.  It was shown that LY379268 protects neurons against 
NMDA toxicity in cell cultures (D'Onofrio et al 2001; Kingston et al 1999), and this 
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benefit is linked to a reduced release of glutamate via presynaptic activation of the 
mGluR2/3 receptors.  In contrast to the understanding of the function of presynaptic 
mGluR2/3 receptors, less is known about the role of metabotropic group II receptors in 
glial cells.  It is known that mGluR3 receptors are expressed in glial cells, but there is no 
expression of mGluR2 (Liu et al 1998; Ohishi et al 1993).  Since a function of glia is the 
synthesis and uptake of glutamate (Winder & Conn 1996), it is likely that activation of 
these receptors by LY379268 results in significant functional benefits.  The role of glial 
cells in neuroprotection was affirmed by Kingston et al (1999), where LY379268 was 
more effective in preventing excitotoxicity in mixed cultures with neuronal and glial cells 
rather than pure neuronal cultures.  The neuroprotection potentially arises from the 
release of proteins such as TGF-β which stem from the activation of glial mGluR3 
(Bruno et al 1998).  The beneficial effects of mGluR3 agonists come from activating the 
mitogen-activated protein (MAP) kinase and the PI-3-kinase pathways (D'Onofrio et al 
2001).  Corti et al (2007) expanded on these earlier studies with knock-out models of 
mGlu2/3 receptors and concluded that neuroprotection came about from mGluR3 
activation by LY379268.  It is probable that neuroprotection from the LY compound 
arises from a combination of activation of presynaptic mGlu2/3 receptors to inhibit 
glutamate release and glial mGluR3 release of trophic proteins. 
 
 The function of LY379268 at mGlur2/3 receptors at excitatory terminals not only 
offers neuroprotection as delineated above, but the benefit of the drug is also seen in 
other diseases where glutamate-mediated transmission plays a role.  A mouse model of 
schizophrenia was developed on the observation that NMDA receptor antagonists such as 
phencyclidine (PCP) or ketamine can heighten preexisting schizophrenic symptoms, and 
is associated with excessive glutamate release in limbic regions (Jentsch & Roth 1999; 
Lorrain et al 2003; Marino & Conn 2002).  Rodents treated with these NMDA 
antagonists have stereotyped hyperkinesia and increased forward locomotion 
(Moghaddam & Adams 1998; Sturgeon et al 1979).  Hyperlocomotion associated with 
PCP or ketamine induction is reversed with LY379268 (Clark et al 2002; Imre et al 2006; 
Lorrain et al 2003).  Motor behaviors are associated with an activated dopamine system 
(Creese & Iversen 1973), and increased dopamine release is a factor in the actions of PCP 
(Freeman & Bunney 1984).  In order to eliminate the possibility of dopamine release as 
the cause of improved behavioral phenotypes, recent studies with rats that are deficient in 
serotonin and dopamine shows that the improved locomotor benefit of LY379268 stems 
from a reduction of evoked glutamate release (Chartoff et al 2005; Swanson et al 2005).  
More recently, another mGlur2/3 agonist, LY404039 was used in a double-blind, 
placebo-controlled Phase 2 clinical trial for schizophrenia.  The outcome of the study 
showed statistically significant improvements of symptoms relative to psychopathology 
(Patil et al 2007).  This clinical trial also showed that LY404039 was safe and well 
tolerated, and it was just as effective as olanzapine with regards to improvement of 
schizophrenic symptoms (Patil et al 2007).  
 
 Recent evidence suggests increased glutamate-mediated transmission, in addition 
to dopamine transmission, might play a role in regulating behavioral actions of drug 
abuse.  Locomotor activity is increased by cocaine under conditions of administration 
with a conditioned stimulus (Hotsenpiller et al 2001).  This study also found increased 
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levels of glutamate in the nucleus accumbens via microdialysis (Hotsenpiller et al 2001).  
Conditioned drug-seeking behaviors brought about by cocaine or heroin are reversed with 
systemic LY379268 (Baptista et al 2004; Bossert et al 2004, 2006; Peters & Kalivas 
2006).  Intraperitoneal injections of the LY compound also reduced hyperlocomotion 
induced from toluene in rats (Riegel et al 2003).  Toluene is a solvent found in many 
inhaled substances that have abuse potential (Miyagawa et al 1984; Riegel et al 2003).  
Thus, LY379268 may show benefit in treating drug addiction, since it was effective in 
reducing drug seeking behavior.  
 
 Treatment of R6/2 mice with LY379268 has been shown in the present studies to 
be beneficial with regards to improvement of motor behavior and neurochemical 
endpoints.  Earlier studies have shown that LY379268 is effective in treating 
neurodegenerative and psychiatric disorders that are associated with increased glutamate 
transmission.  As a newer mGlur2/3 agonist, it has greater affinity and bioavailability 
than the previous generation.  Moreover, a newer generation of the mGlur2/3 agonists, 
LY404039 has been through Phase II of a clinical trial.  The outcome of the trial showed 
that the drug is safe and effective.  LY404039 could soon move to Phase III clinical trials, 
if it is also shown effective R6/2 mice as well as in a genetically more precise model of 
HD as the YAC128 or the Q140.  These results give credence to the choice of mGluR2/3 
agonists as a therapy in diseases where increased glutamate is the underlying cause of the 
pathology.   
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